|
|
|
|
|
TOKYO, JAPAN and WALTHAM, Mass., Dec 15, 2021 - (JCN Newswire) - BostonGene Corporation and NEC Corporation (TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer new windowBostonGene Tumor Portrait Tests in key international markets, including Japan as the first market outside of the U.S.
BostonGene's innovative computational platform performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient's immune system and the effectiveness of all available approved and experimental treatments. BostonGene Tumor Portrait Tests, based on integrated genomic and transcriptomic analysis, propel precision medicine into daily clinical practice and support physicians in actualizing personalized therapy for cancer patients.
Moreover, in NEC's ongoing personalized neoantigen clinical trial that utilizes its AI-driven neoantigen prediction technology, NEC and BostonGene are collaborating to provide molecular characterization of patient tumors. Going forward, the two companies will jointly develop the market for BostonGene Tumor Portrait Tests globally. In Japan, the companies aim to utilize NEC's healthcare and life science network in order to provide Tumor Portrait Tests to hospitals throughout the country.
In 2020, 378,385 people died of cancer in Japan, according to a Ministry of Health, Labor, and Welfare report. This accounts for 27.6% of all deaths that year and equates to one in four people dying of cancer. Leveraging NEC's longstanding relationships with cancer centers, pharma and biotech companies, the organizations will work closely together to demonstrate the critical role of next generation multi-platform analytics combined with cutting-edge software to improve the diagnosis and treatment for cancer patients. Earlier this year, NEC announced an initiative to create healthcare and life science business that utilizes AI and other digital technologies as part of the "creation of future growth businesses" set forth in the 2025 Mid-term Management Plan.
"NEC has been committed to contributing to healthcare for more than half a century, which includes state-of-the-art hospital information systems in Japan. Cancer is now the country's most common cause of death, and NEC has been working with the National Cancer Center Japan since 2016. Today, NEC remains as dedicated as ever to applying our rich experience in AI and analytics for improving patients' outcomes," said Takayuki Morita, President and CEO at NEC Corporation. "BostonGene's offering of deep molecular and immune profiling, coupled with its computational power and analytics, have already improved the quality of care for cancer patients in both academic and community settings in the United States. Supporting BostonGene's international expansion enables us to continue to rapidly drive innovation that improves the standard of care in Japan and abroad."
"NEC has a long history of offering industry leading products and solutions in the field of healthcare both in Japan and globally," said Andrew Feinberg, President and CEO at BostonGene. "Partnering with NEC will allow BostonGene to expedite our international expansion which aims to improve the standard of care for cancer patients around the world."
This agreement expands upon existing collaborations between BostonGene and NEC.
About BostonGene Corporation
BostonGene's mission is to power healthcare's transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
Topic: Press release summary
Source: NEC Corporation
Sectors: MedTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| NEC Corporation |
| Apr 11, 2024 14:10 HKT/SGT |
|
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission |
| Apr 10, 2024 12:36 HKT/SGT |
|
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 |
| Apr 8, 2024 12:45 HKT/SGT |
|
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines |
| Mar 25, 2024 09:08 HKT/SGT |
|
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI |
| Mar 22, 2024 07:38 HKT/SGT |
|
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber |
| Mar 21, 2024 09:02 HKT/SGT |
|
NEC and Tokyo Medical and Dental University use AI to assist self-care for chronic lower back pain |
| Mar 20, 2024 14:30 HKT/SGT |
|
NEC and Skyloom to Pioneer 100 Gbps Space Optical Communications, Transforming Global Internet Connectivity |
| Mar 7, 2024 10:24 HKT/SGT |
|
NEC named to list of Top 100 Global Innovators by Clarivate for 13th consecutive year |
| Mar 5, 2024 08:05 HKT/SGT |
|
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 |
| Mar 4, 2024 10:11 HKT/SGT |
|
NEC and Sumitomo Corporation Sign Strategic Partnership Agreement to Expand Global Sales of the CropScope Agricultural ICT Platform |
| More news >> |
 |
|
|
|
